^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    AKT3 (V-akt murine thymoma viral oncogene homolog 3)

    i
    Other names: AKT3, PKBG, PRKBG, RAC-gamma, V-akt murine thymoma viral oncogene homolog 3
    3ms
    Inhibition of BRG1 suppresses the progression of glioblastoma via repressing oligodendrocyte genes. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    Importantly, BRM014 treatment selectively inhibits the growth of human GBM cells with the OPC signature. In sum, our findings demonstrate that the inhibition of ATPase activity of BRG1 is a promising epigenetic therapy for OPC-like GBM.
    Journal
    |
    TP53 (Tumor protein P53) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • PDGFB (Platelet Derived Growth Factor Subunit B)
    12ms
    Single-cell analysis reveals transcriptomic features and therapeutic targets in primary pulmonary lymphoepithelioma-like carcinoma. (PubMed, Commun Biol)
    Moreover, treatment with either an AKT3 inhibitor or an FGFR2 inhibitor significantly attenuates tumor progression in patient-derived xenograft models. Our findings highlight AKT3 and FGFR2 as potential therapeutic targets and prognostic biomarkers, providing valuable insights for the development of rational targeted therapies and immunotherapeutic strategies.
    Journal • IO biomarker
    |
    FGFR2 (Fibroblast growth factor receptor 2) • AKT3 (V-akt murine thymoma viral oncogene homolog 3)
    over1year
    hsa-miR-181a-5p inhibits glioblastoma development via the MAPK pathway: in-silico and in-vitro study. (PubMed, Oncol Res)
    The in-vitro results were consistent with in-silico results regarding the regulatory effect of hsa-miR-181a-5p on the MAPK pathway, leading to tumor suppression in glioblastoma. hsa-miR-181a-5p inhibits glioblastoma development partially by regulating the signaling factors of the MAPK pathway.
    Preclinical • Journal
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • MAPK1 (Mitogen-activated protein kinase 1) • BAX (BCL2-associated X protein) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • MMP9 (Matrix metallopeptidase 9) • MAPK3 (Mitogen-Activated Protein Kinase 3) • MIR181A1 (MicroRNA 181a-1)
    |
    AKT3 expression
    over1year
    Microarray Analysis of Visceral Adipose Tissue in Obese Women Reveals Common Crossroads Among Inflammation, Metabolism, Addictive Behaviors, and Cancer: AKT3 and MAPK1 Cross Point in Obesity. (PubMed, J Obes)
    VAT confers a complex and blended pathogenic transcriptomic profile in obese patients, where abnormal processes are mainly controlled by activating intracellular signaling pathways that exhibit a high degree of redundancy. Identifying shared cross points between those pathways could allow specific targeting treatments to exert a widespread effect over multiple pathogenic processes.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • MAPK1 (Mitogen-activated protein kinase 1) • AKT3 (V-akt murine thymoma viral oncogene homolog 3)
    |
    MAPK1 overexpression
    over1year
    PA-MSHA exerts potent activity against cetuximab-resistant colorectal cancer through the miR-7-5p/Akt3/Wnt-β-catenin pathway. (PubMed, Transl Cancer Res)
    Finally, we discovered that patients with CRC who had developed cetuximab resistance or disease progression had remarkably decreased serum miR-7-5p levels. PA-MSHA controlled the miR-7-5p/Akt3/Wnt-β-catenin pathway to provide substantial efficacy against cetuximab-resistant CRC.
    Journal
    |
    AKT3 (V-akt murine thymoma viral oncogene homolog 3) • MIR7 (MicroRNA 7)
    |
    AKT3 expression • miR-7-5p overexpression
    |
    Erbitux (cetuximab)
    over1year
    Genotyping of unresectable soft tissue sarcomas (EACR 2024)
    Many sarcomas may be driven by gene fusions. However, further research is needed on a larger group of patients.
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • ATM (ATM serine/threonine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • EP300 (E1A binding protein p300) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • BCL2L2 (BCL2 Like 2) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • DICER1 (Dicer 1 Ribonuclease III) • CHPF (Chondroitin Polymerizing Factor) • SLC25A3 (Solute Carrier Family 25 Member 3) • TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6)
    |
    TruSight Oncology 500 Assay
    almost2years
    Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma. (PubMed, Int J Mol Sci)
    We established MIA-GEM cells, a PDAC cell line resistant to gemcitabine (GEM), a first-line anticancer drug, using the human PDAC cell line-MIA-PaCa-2...Elevated MAST4 expression correlated with a poorer prognosis in PDAC. Consequently, nuclear MAST4 emerges as a potential marker for GEM resistance and poor prognosis, representing a novel therapeutic target for PDAC.
    Journal
    |
    AKT3 (V-akt murine thymoma viral oncogene homolog 3) • FOXO3 (Forkhead box O3) • MAST4 (Microtubule Associated Serine/Threonine Kinase Family Member 4)
    |
    AKT3 overexpression
    |
    gemcitabine
    almost2years
    Differential prognostic values of the three AKT isoforms in acute myeloid leukemia. (PubMed, Sci Rep)
    Curiously, although modestly varying among AML samples, a high AKT1 expression shows in contrast as a strong predictor of a better patient outcome. These data suggest that AKT3 and AKT1 expressions have strong, yet opposite, prognostic values.
    Journal
    |
    NPM1 (Nucleophosmin 1) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • AKT3 (V-akt murine thymoma viral oncogene homolog 3)
    |
    NPM1 mutation • RUNX1 mutation • ASXL1 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • BCOR mutation • AKT2 expression • AKT3 expression
    2years
    The transcription factor TBP promotes hepatocellular carcinoma progression by activating AKT3. (PubMed, Am J Cancer Res)
    Additionally, TBP/AKT3 axis modulated mTOR expression in HCC cells. In conclusion, TBP promotes the transcription of AKT3, thus accelerating the malignant progression of HCC.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • AKT3 (V-akt murine thymoma viral oncogene homolog 3)
    |
    AKT3 expression
    2years
    The Multifunctional Nature of the MicroRNA/AKT3 Regulatory Axis in Human Cancers. (PubMed, Cells)
    Therefore, a better understanding of regulatory miRNA/AKT3 networks may reveal novel biomarkers for the diagnosis of patients with cancer and may provide invaluable information for developing more effective therapeutic strategies. The aim of this review was to summarize current research progress in the isoform-specific functions of AKT3 in human cancers and the roles of dysregulated miRNA/AKT3 in specific types of human cancers.
    Review • Journal
    |
    AKT3 (V-akt murine thymoma viral oncogene homolog 3)
    |
    AKT3 expression
    over2years
    Enhanced Anti-cancer Potency Using a Combination of Oleanolic Acid and Maslinic Acid to Control Treatment Resistance in Breast Cancer. (PubMed, Adv Pharm Bull)
    The results showed that the combination of these two substances showed the highest synergistic effect at the lowest dose and using MA-OA caused cancer cells to undergo apoptosis. The use of combination drugs may reduce the resistance of cancer cells to treatment.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • IGF1 (Insulin-like growth factor 1) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • FOXO3 (Forkhead box O3) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • PRKCB (Protein Kinase C Beta)
    |
    CDKN1B expression
    over2years
    Sanguisorba officinalis L. enhances the 5-fluorouracil sensitivity and overcomes chemoresistance in 5-fluorouracil-resistant colorectal cancer cells via Ras/MEK/ERK and PI3K/Akt pathways. (PubMed, Heliyon)
    Furthermore, DY may prevail over chemoresistance through the Ras/MEK/ERK and PI3K/Akt pathways. These findings imply that DY may be a potential drug for clinical treatment or adjuvant treatment of drug-resistant CRC.
    Journal
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • BMI1 (BMI1 proto-oncogene, polycomb ring finger) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    HIF1A expression
    |
    5-fluorouracil